Abbreviated Prescribing Information
FluMist Trivalent

Presentation: Trivalent contains three vaccine virus strains: an A/H1N1 strain, an A/H3N2 strain and a B strain from the B/Victoria lineage. Indication and dosage: Vaccine indicated for active immunization for the prevention of influenza disease caused by influenza virus subtypes A and type B contained in the vaccine. Use in persons 2 through 49 years of age. For age 2‐8 years, 1 or 2 doses (0.2 mL each) depending on vaccination history (if 2 doses, administer at least 1 month apart); 9‐49 years, 1 dose, 0.2 mL. Contraindications: Severe allergic reaction (e.g., anaphylaxis) to any component of FluMist Trivalent, including egg protein, or after a previous dose of any influenza vaccine. Concomitant aspirin therapy or aspirin-containing therapy in children and adolescents through 17 years of age. Precautions:  age < 5 years with recurrent wheezing; may be at increased risk of wheezing in persons of any age with asthma; Guillain‐ Barré syndrome; Immunocompromised persons; individuals with underlying medical condition that may predispose them to complications following wild‐type influenza infection; acute allergic reactions; pregnancy; lactation. Interaction: Aspirin or aspirin-containing therapy; Antiviral drugs that are active against influenza A and/or B. Adverse Reactions: The most common solicited adverse reactions (≥ 10% in vaccine recipients and at least 5% greater than in placebo recipients) reported were runny nose or nasal congestion (ages 2 years through 49 years), fever over 100°F (children ages 2 years through 6 years), and sore throat (adults ages 18 years through 49 years). Full local prescribing information is available upon request. API.HK.FLU.0425 

HK-11947 22/07/2025